Observational studyBMC infectious diseases2025
Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03108794 (A Nation-wide Hospital-based Hepatitis B Registry), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B
Who cites it
1 citing paper in PubMed.
- Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiscrepancies and uncertainties persist across various guidelines regarding specific age categories and their association with the risk of hepatocellular carcinoma (HCC). Simultaneously, a more nuanced examination is warranted to ascertain whether the association between age and HCC risk adheres strictly to a linear pattern.
aimsTo elucidate the relationship between age and risk of HCC in individuals with hepatitis B virus (HBV)-related cirrhosis.
methodsA retrospective study conducted across two medical centers enrolled individuals with HBV-related cirrhosis, treating baseline age as a categorical variable to assess the risk of developing HCC. Restricted cubic spline regression was employed to scrutinize potential non-linear associations between age and HCC risk.
resultsOf the 434 patients recruited, over a median antiviral treatment duration of 43 months, HCC developed in 45 patients. Baseline age exhibited an independent association with on-treatment HCC risk, demonstrating a non-linear parabolic-like pattern with a threshold value of 59. Below the threshold, age was linked to an increased risk of HCC (aHR 1.104; p = 0.004), while this heightened risk persisted above the threshold. In comparison to the middle-aged group, the youth group was less prone to HCC development (HR 0.3; p = 0.001). These associations remained robust even after adjustments for covariates.
conclusionsThe interplay between baseline age and on-treatment HCC risk exhibited a non-linear, parabolic-like trajectory. Early initiation of antiviral therapy is recommended to mitigate the escalating risk of HCC in individuals with HBV-related cirrhosis. Additionally, enhanced monitoring for HCC is advised for individuals initiating antiviral therapy above the age of 50 years.
trial registrationCR-HepB (China Registry of Hepatitis B) is a nationwide hospital-based electronic platform in China, used to demonstrate the clinical pattern and treatment profile of chronic HBV infection, evaluate long-term efficacy and safety of antiviral therapy and provide real-world evidence for policy-making in China.Up to 2018, 47 hospitals have joined the CR-HepB and our hospital is one of the branch centers. CLINICALTRIALS: gov ID: NCT03108794. Registration Date: June 30, 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.